Optimizing Dermatology Surescripts Integration for Biologic Therapies

Klivira's advanced platform delivers seamless dermatology Surescripts integration, specifically designed to automate prior authorizations for high-cost biologic and specialty drug therapies common in skin care.

Revenue cycle directors and prior authorization coordinators in dermatology practices face significant challenges managing the volume and complexity of PAs for chronic conditions. Biologics for psoriasis, atopic dermatitis, and hidradenitis suppurativa frequently require rigorous documentation and timely re-authorizations. Leveraging Surescripts ePA can significantly streamline the pharmacy benefit prior authorization process, enhancing efficiency and patient access to critical treatments.

The Strategic Advantage of Surescripts ePA in Dermatology

For dermatology practices, the category of specialty drug ePA and eligibility is paramount. Surescripts integration enables direct, electronic submission of prior authorization requests for pharmacy-benefit medications, bypassing time-consuming faxes and portal navigation. This is particularly critical for biologics like Dupixent, Cosentyx, Tremfya, and Skyrizi, where rapid approval impacts patient treatment adherence and outcomes.

Key Dermatology Therapies Benefiting from Surescripts ePA

**Biologics for Psoriasis/PsA:** TNF inhibitors (e.g., adalimumab, etanercept), IL-17 inhibitors (e.g., secukinumab, ixekizumab), IL-23 inhibitors (e.g., guselkumab, risankizumab), and oral targeted therapies (e.g., apremilast).
**Biologics for Atopic Dermatitis:** dupilumab, tralokinumab, and oral JAK inhibitors.
**Hidradenitis Suppurativa Biologics:** adalimumab, secukinumab.
**Other Specialty Topicals:** High-cost topical medications often requiring pharmacy benefit PA.

Integrating Surescripts ePA with EMRs for Dermatology Workflows

Effective dermatology Surescripts integration hinges on robust EMR connectivity. Klivira integrates with major EMR systems, pulling necessary patient demographics, diagnoses, and medication history directly from the chart. This reduces manual data entry, minimizes errors, and ensures that ePA requests submitted via Surescripts contain all required clinical context, aligning with guidelines from bodies like the AAD for conditions such as psoriasis and atopic dermatitis.

Essential Documentation for Dermatology Biologic PAs

**Disease Severity Scores:** PASI/BSA for psoriasis, EASI/SCORAD for atopic dermatitis.
**Trial and Failure Documentation:** Prior topical therapy, phototherapy, or conventional systemic therapies (e.g., methotrexate, cyclosporine).
**Pre-Biologic Screenings:** Documentation of TB and hepatitis screenings.
**Age-Appropriate Criteria:** Especially for pediatric indications of biologics like Dupixent.
**Step Therapy Compliance:** Adherence to payer-mandated treatment sequences.

Beyond Surescripts: Comprehensive PA Management for Dermatology

While Surescripts excels at pharmacy benefit ePA, dermatology practices also navigate medical benefit PAs for procedures like Mohs micrographic surgery or advanced skin cancer treatments. Klivira's platform provides a holistic solution, managing both NCPDP SCRIPT-based ePA for drugs and X12 278 transactions for medical procedures. This ensures all PA types, including periodic re-authorizations for chronic biologic treatments, are handled efficiently, reducing common denial reasons such as step therapy non-compliance or insufficient disease severity documentation.

Frequently asked questions

How does Surescripts integration specifically benefit dermatology practices?

Surescripts integration primarily streamlines prior authorizations for pharmacy-benefit specialty drugs and biologics, which are common in dermatology for conditions like psoriasis and atopic dermatitis. It automates the submission process, reducing manual work and accelerating the approval cycle for high-cost medications.

Does Surescripts handle prior authorizations for procedures like Mohs surgery?

Surescripts ePA is designed for pharmacy benefit medications. Procedures like Mohs micrographic surgery typically fall under the medical benefit and require prior authorization through different channels, often utilizing X12 278 transactions. Klivira's platform manages both types of prior authorizations for comprehensive coverage.

What EMR data is leveraged for dermatology PAs via Surescripts integration?

Our integration pulls critical data points such as patient demographics, diagnostic codes (e.g., for psoriasis, atopic dermatitis), documented disease severity scores (PASI, EASI, BSA), and medication history. This ensures that the ePA request submitted via Surescripts is pre-populated with the necessary clinical information to meet payer requirements.

How does Klivira address re-authorization for chronic biologic treatments in dermatology?

Klivira's platform includes workflow capabilities for managing periodic re-authorizations, typical for chronic biologic treatments. It can track re-authorization cycles, proactively alert staff, and facilitate the submission of updated clinical documentation via Surescripts or other channels as required, ensuring continuity of care.